Long-term survivors of glioblastoma multiforme (GBM) are at high risk of developing second primary neoplasms, including leukemia. For these patients, the use of classic tyrosine kinase inhibitors (TKIs), such as imatinib mesylate, is…
DDSC
Department of Drug Chemistry and Technologies
Sapienza University of Rome
Laboratory affiliated to Istituto Pasteur Italia
Fondazione Cenci Bolognetti
Piazzale Aldo Moro 5, I-00185 Roma, Italy
Phone: +39 06 4991 3800 – Fax: +39 06 49913993
Email: info@romanosilvestri.it